Merging deep tech and biomedical science expertise, ChronicleBio aims to accelerate breakthroughs for millions living with complex chronic conditions

New venture harnesses multi-omic data and AI to develop the largest platform on complex chronic illnesses to drive breakthroughs in POTS, ME/CFS, Long COVID, and other neuroimmune disorders

SAN FRANCISCO, Aug. 5, 2025 /PRNewswire/ -- ChronicleBio, a techbio startup focused on radically accelerating insights on neuroimmune disorders, officially launched Tuesday with a bold mission: to build the world's richest, AI-ready data platform for historically overlooked conditions like POTS, ME/CFS, Long COVID, and other complex chronic conditions.

ChronicleBio is uniquely led by a founding team that unites elite tech, healthcare, and life sciences:

• Fidji Simo (Co-founder), current CEO of Instacart and the incoming CEO of OpenAI's applications division, brings deep expertise in consumer-scale technology, product innovation, and health systems transformation.
• Rohit Gupta (Co-founder & CEO), a biobanking and precision medicine leader who previously oversaw centers at Stanford and UCSF, is the leading scientific and strategic force behind ChronicleBio.
• Rishi Reddy (Co-founder & Executive Chairman), of Tarsadia Investments, brings an entrepreneurial and venture-backed perspective and a track record in health and life sciences investing.

Together, they are tackling a critical gap in biomedical research. ChronicleBio is creating a scalable, ethically driven data ecosystem, integrating clinical, molecular, biospecimen, and patient-reported insights to drive biomarker discovery, patient stratification, and precision therapeutic development.

"Entire communities of patients have been ignored for too long, not because their conditions aren't debilitating and prevalent, but because the systems weren't built to understand them," said Fidji Simo, co-founder of ChronicleBio. "ChronicleBio is developing a future where patients can enlist in research, and where the data we collect from them goes directly towards better diagnostics and therapeutics. By building these critical missing datasets and leveraging the massive advances in AI, we aim to accelerate the path to cures."

These complex chronic conditions impact nearly 300 million people worldwide, but remain woefully understudied, leaving patients hopeless and without meaningful treatments. It's a disease space desperate for data, and ChronicleBio is offering the scalable solutions to provide it.

"Neuroimmune disorders remain some of the most poorly understood in medicine and not for lack of interest, but because the underlying data simply doesn't exist at the scale or structure required for serious breakthroughs," said Rohit Gupta, co-founder and CEO of ChronicleBio. "We're empowering patients and clinicians to get involved in this effort to grow our research-grade biobank and AI-ready data platform so we can close that gap and provide the tools to finally interrogate these diseases with scientific rigor and precision, bringing an end to complex chronic conditions."

ChronicleBio partners directly with patients, clinics, and research collaborators to generate longitudinal, multi-modal datasets, including genomics, immune profiling, and real-world outcomes designed for exploration and clinical trial readiness. Its platform is already being used in multiple high-integrity clinics in the U.S. and India, as well as through research collaborations with thousands of patients contributing data and biosamples.

"We're creating an ecosystem with global reach, designed not just to generate data, but to fundamentally shift how we discover, develop, and deliver treatments at scale. The opportunity for impact—scientifically, medically, and societally—is enormous," said Rishi Reddy, co-founder and Executive Chairman of ChronicleBio. "We're building the foundational infrastructure for a massive medical need that has been hiding in plain sight."

ChronicleBio's founding vision isn't just ambitious. It's personal. Both Simo and Reddy have been diagnosed with at least one of the very conditions the company is focused on researching. Gupta's family also suffers from neuroimmune disorders. The group's world-class expertise is outshined only by its heartfelt determination to rewrite the scientific narrative for the millions of patients overlooked by traditional research and transform lived experience into actionable discovery.

ChronicleBio's approach includes:

• A global biobank platform collecting and connecting data on neuroimmune illnesses
• A proprietary, AI-ready data engine designed to integrate multi-omic, clinical, and real-world evidence
• Strategic partnerships with clinics, research consortia, and biotech sponsors looking to unlock hard-to-crack therapeutic areas
• A decentralized clinical trial network accelerating drug development through real-world access to patients and clinicians

For more information, visit chroniclebio.com or follow ChronicleBio on LinkedIn, X, Instagram, and Facebook.

Media Contact:
[email protected]

SOURCE ChronicleBio